| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Heba M Mansour, Ahmed F Mohamed, Mahmoud M Khattab, Aiman S El-Khati. Lapatinib ditosylate rescues motor deficits in rotenone-intoxicated rats: Potential repurposing of anti-cancer drug as a disease-modifying agent in Parkinson's disease. European journal of pharmacology. 2023-06-29. PMID:37385578. |
parkinson's disease (pd) is a neurodegenerative disorder characterized by motor deficits induced by dopaminergic neuronal death in the substantia nigra (sn). |
2023-06-29 |
2023-08-14 |
rat |
| Heba M Mansour, Ahmed F Mohamed, Mahmoud M Khattab, Aiman S El-Khati. Lapatinib ditosylate rescues motor deficits in rotenone-intoxicated rats: Potential repurposing of anti-cancer drug as a disease-modifying agent in Parkinson's disease. European journal of pharmacology. 2023-06-29. PMID:37385578. |
in the current study, administration of 100 mg/kg lap in rotenone-treated rats for 21 days ameliorates motor impairment, debilitated histopathological alterations, and revived dopaminergic neurons by increasing tyrosine hydroxylase (th) expression in sn, along with increased dopamine level. |
2023-06-29 |
2023-08-14 |
rat |
| Chen-Pei Lin, Lydian E J Knoop, Irene Frigerio, John G J M Bol, Annemieke J M Rozemuller, Henk W Berendse, Petra J W Pouwels, Wilma D J van de Berg, Laura E Jonkma. Nigral Pathology Contributes to Microstructural Integrity of Striatal and Frontal Tracts in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2023-06-22. PMID:37347552. |
motor and cognitive impairment in parkinson's disease (pd) is associated with dopaminergic dysfunction that stems from substantia nigra (sn) degeneration and concomitant α-synuclein accumulation. |
2023-06-22 |
2023-08-14 |
Not clear |
| Dongling Zhang, Liche Zhou, Junye Yao, Yuting Shi, Hongjian He, Hongjiang Wei, Qiqi Tong, Jun Liu, Tao W. Increased Free Water in the Putamen in Idiopathic REM Sleep Behavior Disorder. Movement disorders : official journal of the Movement Disorder Society. 2023-06-21. PMID:37342973. |
it has been suggested that the loss of nigrostriatal dopaminergic axon terminals occurs before the loss of dopaminergic neurons in the substantia nigra (sn) in parkinson's disease (pd). |
2023-06-21 |
2023-08-14 |
Not clear |
| Mohammed Alrouji, Hayder M Al-Kuraishy, Ali K Al-Buhadily, Ali I Al-Gareeb, Engy Elekhnawy, Gaber El-Saber Batih. DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson's disease: a mutual relationship. Pharmacological reports : PR. 2023-06-03. PMID:37269487. |
parkinson's disease (pd) usually occurs due to the degeneration of dopaminergic neurons in the substantia nigra (sn). |
2023-06-03 |
2023-08-14 |
Not clear |
| Yea-Hyun Leem, Do-Yeon Kim, Jung-Eun Park, Hee-Sun Ki. Necrosulfonamide exerts neuroprotective effect by inhibiting necroptosis, neuroinflammation, and α-synuclein oligomerization in a subacute MPTP mouse model of Parkinson's disease. Scientific reports. vol 13. issue 1. 2023-05-31. PMID:37258791. |
furthermore, nsa inhibited the phosphorylation, ubiquitylation, and oligomerization of mlkl, all of which are associated with mlkl cell death-inducing activity in dopaminergic cells in the substantia nigra (sn). |
2023-05-31 |
2023-08-14 |
mouse |
| Yiyuan Xu, Xinyu Huang, Xin Geng, Fei Wan. Meta-analysis of iron metabolism markers levels of Parkinson's disease patients determined by fluid and MRI measurements. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS). vol 78. 2023-05-24. PMID:37224790. |
parkinson' s disease (pd) is a progressive neurodegenerative disease featured neuropathologically by the loss of dopaminergic neurons of the substantia nigra (sn). |
2023-05-24 |
2023-08-14 |
Not clear |
| Mohammed Alrouji, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Athanasios Alexiou, Marios Papadakis, Majid S Jabir, Hebatallah M Saad, Gaber El-Saber Batih. NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective. Journal of cellular and molecular medicine. 2023-05-21. PMID:37210624. |
particularly, insulin resistance (ir) in t2dm promotes the degeneration of dopaminergic neurons in the substantia nigra (sn). |
2023-05-21 |
2023-08-14 |
Not clear |
| Mohammed Alrouji, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Athanasios Alexiou, Marios Papadakis, Majid S Jabir, Hebatallah M Saad, Gaber El-Saber Batih. NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective. Journal of cellular and molecular medicine. 2023-05-21. PMID:37210624. |
systemic activation of nlrp3 inflammasome promotes the accumulation of α-synuclein and degeneration of dopaminergic neurons in the sn. |
2023-05-21 |
2023-08-14 |
Not clear |
| Juan García-Revilla, Antonio Boza-Serrano, Yiyun Jin, Devkee M Vadukul, Jesús Soldán-Hidalgo, Lluís Camprubí-Ferrer, Marta García-Cruzado, Isak Martinsson, Oxana Klementieva, Rocío Ruiz, Francesco A Aprile, Tomas Deierborg, José Luis Vener. Galectin-3 shapes toxic alpha-synuclein strains in Parkinson's disease. Acta neuropathologica. 2023-05-18. PMID:37202527. |
parkinson's disease (pd) is a neurodegenerative and progressive disorder characterised by intracytoplasmic inclusions called lewy bodies (lb) and degeneration of dopaminergic neurons in the substantia nigra (sn). |
2023-05-18 |
2023-08-14 |
mouse |
| Fei Tang, Liu-Yao Zhou, Ping Li, Ling-Ling Jiao, Kang Chen, Yu-Jie Guo, Xu-Long Ding, Si-Yu He, Biao Dong, Ru-Xiang Xu, Huan Xiong, Peng Le. Inhibition of ACSL4 Alleviates Parkinsonism Phenotypes by Reduction of Lipid Reactive Oxygen Species. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2023-05-03. PMID:37133631. |
here, we report that acsl4 expression in the substantia nigra (sn) was increased in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp)-treated model of pd and in dopaminergic neurons in pd patients. |
2023-05-03 |
2023-08-14 |
mouse |
| Fei Tang, Liu-Yao Zhou, Ping Li, Ling-Ling Jiao, Kang Chen, Yu-Jie Guo, Xu-Long Ding, Si-Yu He, Biao Dong, Ru-Xiang Xu, Huan Xiong, Peng Le. Inhibition of ACSL4 Alleviates Parkinsonism Phenotypes by Reduction of Lipid Reactive Oxygen Species. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2023-05-03. PMID:37133631. |
knockdown of acsl4 in the sn protected against dopaminergic neuronal death and motor deficits in the mptp mice, while inhibition of acsl4 activity with triacsin c similarly ameliorated the parkinsonism phenotypes. |
2023-05-03 |
2023-08-14 |
mouse |
| Yunan Zhou, Zhihui Li, Chunling Chi, Chunmei Li, Meimei Yang, Bin Li. Identification of Hub Genes and Potential Molecular Pathogenesis in Substantia Nigra in Parkinson's Disease via Bioinformatics Analysis. Parkinson's disease. vol 2023. 2023-04-24. PMID:37089789. |
one of the crucial pathological features of pd is the loss of dopaminergic neurons in the substantia nigra (sn). |
2023-04-24 |
2023-08-14 |
Not clear |
| Hayder M Al-Kuraishy, Ali I Al-Gareeb, Yaser Hosny Ali Elewa, Mahmoud Hosny Zahran, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batih. Parkinson's Disease Risk and Hyperhomocysteinemia: The Possible Link. Cellular and molecular neurobiology. 2023-04-19. PMID:37074484. |
parkinson's disease (pd) is one of the most common degenerative brain disorders caused by the loss of dopaminergic neurons in the substantia nigra (sn). |
2023-04-19 |
2023-08-14 |
Not clear |
| Cláudia Saraiva, Jéssica Lopes-Nunes, Marta Esteves, Tiago Santos, Ana Vale, Ana Clara Cristóvão, Raquel Ferreira, Liliana Bernardin. CtBP Neuroprotective Role in Toxin-Based Parkinson's Disease Models: From Expression Pattern to Dopaminergic Survival. Molecular neurobiology. 2023-04-15. PMID:37060501. |
herein, we showed that ctbp1 and ctbp2 are expressed in neurons, dopaminergic neurons, astrocytes, and microglia in the substantia nigra (sn) and striatum of adult mice. |
2023-04-15 |
2023-08-14 |
mouse |
| Yi Zhuo, Xuan Li, Zhengwen He, Ming L. Pathological mechanisms of neuroimmune response and multitarget disease-modifying therapies of mesenchymal stem cells in Parkinson's disease. Stem cell research & therapy. vol 14. issue 1. 2023-04-11. PMID:37041580. |
parkinson's disease (pd) is a neurodegenerative disease characterized by the degeneration of dopaminergic neurons in the substantia nigra (sn); the etiology and pathological mechanism of the disease are still unclear. |
2023-04-11 |
2023-08-14 |
Not clear |
| Zihua Liu, Qiang Ye, Ying Jian. Transcriptomic analysis: the protection of over-expression thioredoxin reductase 1 in Parkinson's disease. Chinese neurosurgical journal. vol 9. issue 1. 2023-04-04. PMID:37013627. |
the pathologic characteristic feature is the loss of dopaminergic neurons in the substantia nigra (sn). |
2023-04-04 |
2023-08-14 |
Not clear |
| Hung-Li Wang, Yi-Chuan Cheng, Tu-Hsueh Yeh, Han-Fang Liu, Yi-Hsin Weng, Rou-Shayn Chen, Yi-Chun Chen, Juu-Chin Lu, Tsong-Long Hwang, Kuo-Chen Wei, Yu-Chuan Liu, Yu-Ting Wang, Chia-Chen Hsu, Tai-Ju Chiu, Ching-Chi Chi. HCH6-1, an antagonist of formyl peptide receptor-1, exerts anti-neuroinflammatory and neuroprotective effects in cellular and animal models of Parkinson's disease. Biochemical pharmacology. 2023-03-31. PMID:37001680. |
hch6-1 ameliorated rotenone-induced microglial activation, upregulation of fpr1 mrna, activation of nlrp3 inflammasome, cell death of sn dopaminergic neurons and pd motor deficit in mice. |
2023-03-31 |
2023-08-14 |
mouse |
| Hyeon-Man Bae. Diffusion Measures of Subcortical Structures Using High-Field MRI. Brain sciences. vol 13. issue 3. 2023-03-29. PMID:36979201. |
the pathology of parkinson's disease (pd) involves the death of dopaminergic neurons in the substantia nigra (sn), which slowly influences downstream basal ganglia pathways as dopamine transport diminishes. |
2023-03-29 |
2023-08-14 |
human |
| Mohammed Alrouji, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Hebatallah M Saad, Gaber El-Saber Batih. A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson's disease: beneficial or detrimental effects. Inflammopharmacology. 2023-03-24. PMID:36961665. |
parkinson's disease (pd) is an advanced neurodegenerative disease (ndd) caused by the degeneration of dopaminergic neurons (dns) in the substantia nigra (sn). |
2023-03-24 |
2023-08-14 |
Not clear |